Abstract PS3-01-14: Oncological and Surgical Outcomes of Risk Reducing Nipple Sparing Mastectomy in Germline Pathogenic Variant Carriers

View at publisher
Authors: Francisco Pimentel Cavalcante, Marcelo Antonini, Antonio Luis Frasson, Idam de Oliveira Junior, F. Palermo Brenelli, Anastasio Berrettini, G. N. Garcia, F. Bagnoli, F. Pereira Zerwes, Eduardo Camargo Millen, André P. L. Mattar, J. P. Reis
+12 more Rogério Fenile, R. Aloísio da Costa Vieira, H.R. de Oliveira Filho, Martina Lichtenfels, Renata Lazari Sandoval, P. L. Quidute, Renato Zocchio Torresan, L. M. Zuliani, M. M. Bortoluzzi, A. Dominique Nascimento Lima, Rodrigo Santa Cruz Guindalini, N. Polidorio
Cited by: 0

Abstract

Abstract Background: Nipple-sparing mastectomy (NSM) is increasingly adopted as a risk-reducing surgical approach in women with germline pathogenic variants (PVs). Although oncologic outcomes are well established for risk-reducing mastectomies in BRCA1/2 carriers, data are limited for NSM as well as for individuals with other high- and moderate-penetrance PVs. This study aimed to evaluate the incidence of new breast cancer, cosmetic outcomes and surgical complications following risk-reducing NSM in PV carriers. Methods: We conducted a multicenter retrospective cohort study of risk-reducing NSM performed between 2008 and 2025 across 12 institutions. Asymptomatic patients (bilateral risk-reducing mastectomy [BRRM]) or individuals with unilateral breast cancer (contralateral risk-reducing mastectomy [CRRM]) were included. Patients with occult malignancy detected at NSM were excluded. Crude incidence rates were used to report new breast cancer diagnoses and complications. Cosmetic outcomes were assessed using the Harvard four-point scale. Risk factors for complications were analyzed using univariable (UVA) and multivariable (MVA) analyses. Results: A total of 524 patients underwent risk-reducing NSM: 219 BRRM and 305 CRRM (743 mastectomies). Most patients carried BRCA1 (46.0%) or BRCA2 (25.4%) PVs, followed by TP53 (15.1%). Median age was 40 years (range 20-68). At a median follow-up of 41.2 months (IQR 13.1-60.3), three patients (0.6%) developed breast cancer: one nodal recurrence post-BRRM, and two flap recurrences post-CRRM (BRCA1 [n=2] and BRCA2 [n=1]). Breast cancer-related death occurred in three patients (0.6%), all following CRRM. Cosmetic outcomes were favorable, with 90% rated as excellent or good. Surgical complications occurred in 101 patients (19.3%), more frequently after CRRM (24.6%) than BRRM (11.9%) (p

Fields of Study & Subjects

BRCA gene mutations in cancer Breast Implant and Reconstruction Breast Lesions and Carcinomas

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
4_Supplement
Pages
PS3–01
Publication date
17 February 2026
Language
EN